Trials / Terminated
TerminatedNCT04560010
TXA in Anticoagulated Patients Study
The Effect of Tranexamic Acid in Anticoagulated Patients Undergoing Total Shoulder Athroplasty
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- NYU Langone Health · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, single-blind, single-center study comparing calculated total blood loss, surgical drain output and hematoma formation in anticoagulated patients who receive 2 doses of Tranexamic Acid (TXA) versus control group undergoing anatomical and reverse total shoulder arthroplasty (TSA). Patients will be randomized to either receive 2 doses of IV TXA, first dose prior to surgical incision and second dose given 3 hours later or to the control group, where no TXA will be administered.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tranexamic Acid Injection (TXA) | Injection of 1 gram of IV TXA before surgical plus 1 gram of IV TXA three hours later |
Timeline
- Start date
- 2020-10-06
- Primary completion
- 2023-03-11
- Completion
- 2023-03-11
- First posted
- 2020-09-23
- Last updated
- 2024-03-26
- Results posted
- 2024-03-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04560010. Inclusion in this directory is not an endorsement.